Skip to content
mapperlab
← Dashboard
Stock

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
Latest close $3.395 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
6
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 14, 2024Feb 14, 2025Nov 13, 2025May 14, 2026
Now
5

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$10$3.39-66%
Two Sigma Investments re-entered$10$3.39-66%
D.E. Shaw$10$3.39-66%
AQR Capital Management re-entered$10$3.39-66%
Millennium Management$10$3.39-66%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Renaissance Technologies 2× in & out→ $3.52+40%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at IOVANCE BIOTHERAPEUTICS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
9
Filings · last 90d
15
Total on file
285
Recent SEC buffer
Most recent
Jun 9, 2026

30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 285 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · IOVANCE BIOTHERAPEUTICS, INC.

Annual figures sourced directly from IOVANCE BIOTHERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$263.5M
FY2025+61% YoY
Net income
-$390.98M
FY2025-5% YoY
EPS (diluted)
$-1.09
FY2025+15% YoY
Free cash flow(?)
-$336.24M
FY2025+8% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for IOVANCE BIOTHERAPEUTICS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Renaissance TechnologiesQ1 2026Q2 2026$2.52$3.52+40%
Two Sigma InvestmentsQ2 2025open$1.76$3.39+93%
Renaissance TechnologiesQ2 2025Q4 2025$1.71$2.41+41%
AQR Capital ManagementQ1 2025open$5.57$3.39-39%
Citadel AdvisorsQ3 2024open$10$3.39-66%
Two Sigma InvestmentsQ3 2024Q1 2025$10$5.57-45%
D.E. ShawQ3 2024open$10$3.39-66%
AQR Capital ManagementQ3 2024Q4 2024$10$8.59-15%
Millennium ManagementQ3 2024open$10$3.39-66%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.